Research and Markets: The Outlook for Cardiovascular Risk Factors: In the US, Direct and Indirect costs of Cardiovascular Disease, CVD, and Stroke in 2003 Estimated at Almost $352bn.Business Editors/Health/Medical Writers DUBLIN, Ireland--(BUSINESS WIRE)--April 23, 2004 Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Outlook for Cardiovascular Risk Factors: Epidemiology, Market and Pipeline analysis to their offering. The Outlook for Cardiovascular Risk Factors: Epidemiology, market and pipeline analysis, evaluates current and future growth prospects for pharma companies to 2008 in five major cardiovascular risk factors that can be moderated by pharmacotherapy pharmacotherapy /phar·ma·co·ther·a·py/ (-ther´ah-pe) treatment of disease with medicines. phar·ma·co·ther·a·py n. Treatment of disease through the use of drugs. ; hypertension, dyslipidemia, diabetes, obesity and smoking. Cumulatively, the value of these markets was approximately $66bn in 2002 or around one-fifth of the global pharmaceutical market. In the US alone, the direct and indirect costs Indirect costs are costs that are not directly accountable to a particular function or product; these are fixed costs. Indirect costs include taxes, administration, personnel and security costs. See also
Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease (CVD CVD Cardiovascular disease, see there ) and stroke in 2003 are estimated at almost $352bn. Reducing these costs by appropriately treating cardiovascular risk factors has become a major focus of the pharmaceutical industry and healthcare payors. This report sets out to define cardiovascular risk factors and how identifying links to them sooner, will lead to a decline in CVD, resulting in massive cost savings for both pharma companies and healthcare payors. Treating risk factors is preventive medicine preventive medicine, branch of medicine dealing with the prevention of disease and the maintenance of good health practices. Until recently preventive medicine was largely the domain of the U.S. at its most challenging and this report provides insights into the risk factors that pharma companies need to overcome this battle - it can be won...let this report help you. Key findings in this report - The global anti-hypertensive market was worth approximately $36.8bn in 2002. As the only class to remain entirely patent protected, future growth within the global anti-hypertensive market will be driven by the angiotensin receptor The angiotensin receptors are a class of G protein-coupled receptors with angiotensins as ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the main effector hormone. blockers. - Pfizer is developing a single pill combination of Lipitor and its antihypertensive antihypertensive /an·ti·hy·per·ten·sive/ (-ten´siv) counteracting high blood pressure, or an agent that does this. an·ti·hy·per·ten·sive adj. Reducing high blood pressure. n. Norvasc. Currently in registration in the US, the product, branded Caduet, could generate sales of $1bn in 2008, although it is likely that other combinations of statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein and anti-hypertensives will eventually prove more effective. - The prevalance of diabetes is rising rapidly, up from 30 million globally in 1985 to a forecast 300 million in 2005. This reflects growth of the aging population, adoption of unhealthy diets, obesity and sedentary lifestyles. - The current obesity market is worth just less than $800m and has the potential to expand to around $1.6bn by 2010. Expansion will primarily be driven by the reimbursement and wider availability of anti-obesity therapies, based on the growing realization that treatment leads to a reduction in expensive co-morbidities and mortality. For more information visit http://www.researchandmarkets.com/reports/c1477 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion